MAR 25, 2019 10:59 AM PDT

Discovery of Biomarker Target for Melanoma

WRITTEN BY: Nouran Amin

According to a study published in the journal Cancer Research, researchers have discovered a biomarker that could serve as a possible therapeutic target for melanoma. The marker is microphthalmia-associated transcription factor (MITF)—which is is a protein that plays a crictcal role in the maintenance of the melanocyte lineage (cells that make melanin), as well as the differentiation of normal and malignant melanocytes and melanoma cell survival.

Melanoma in skin biopsy with H&E stain — this case may represent superficial spreading melanoma. Credit: Wikipedia/CC BY-SA 3.0

"We have now detected the first useful chemical inhibitor of MITF," said corresponding author Rhoda Alani, MD, the Herbert Mescon Chair of Dermatology at Boston University School of Medicine.

Over the past decade genetic mutations in human melanomas have been extensively examined—regardless, the role of epigenetic alterations in the development and progression of melanomas is still not well understood.

Specifically, scientists discovered that the inhibition of the epigenetic p300 Histone Acetyltransferase (HAT) enzyme stops the growth of human melanoma cells and cells that express the MITF protein are sensitive to this inhibition. The inhibition can hold many broad implications for the treatment of pigmented lesions in the skin which could potentially be used for the topical treatment of hyperpigmentation.

The study opens the doors to the endless pursuit for additional epigenetic approaches to cancers.

"When human melanoma cell lines were evaluated for growth effects using the chemical inhibitor of p300 HAT, the cell lines that were most sensitive to drug treatment were those that expressed high levels of MITF suggesting that MITF expression levels can predict melanoma sensitivity to such therapies," explained Alani, who also is chief of dermatology at Boston Medical Center.

Source: EurekAlert

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
APR 11, 2022
Cancer
What is a Cancer Center?
APR 11, 2022
What is a Cancer Center?
Over 50 years ago, President Richard Nixon signed the National Cancer Act of 1971, a landmark piece of legislation ...
APR 16, 2022
Neuroscience
A New Approach to Seizure Treatment
APR 16, 2022
A New Approach to Seizure Treatment
There are many types of epilepsy, a brain disorder that causes recurrent seizures or periods of altered behaviors or sen ...
APR 21, 2022
Clinical & Molecular DX
An Emerging Need to Diagnose Maladaptive Daydreaming
APR 21, 2022
An Emerging Need to Diagnose Maladaptive Daydreaming
Maladaptive daydreaming (MD), also called daydreaming disorder, occurs in people who experience intense daydreams o ...
MAY 25, 2022
Neuroscience
Exploring Drug Targets in Neurodegenerative Diseases
MAY 25, 2022
Exploring Drug Targets in Neurodegenerative Diseases
Introduction Life expectancy has increased globally over the last several decades. However, longer life expectancy comes ...
MAY 26, 2022
Cannabis Sciences
Cannabis Crystal Polymorphism
MAY 26, 2022
Cannabis Crystal Polymorphism
A new published commentary in the Journal of Cannabis Research indicated that cannabis crystallinity may determine level ...
JUN 24, 2022
Drug Discovery & Development
Pain Medications with High Abuse Potential More Likely to Achieve Approval
JUN 24, 2022
Pain Medications with High Abuse Potential More Likely to Achieve Approval
Researchers found that pain medications with a high potential for abuse are more likely to be approved than medications ...
Loading Comments...